Sesen Bio was founded in 2009 as a spin-off drug development and technology transfer collaboration between Harvard Medical School, MIT, and the Dana Farber Cancer Institute. From the start, the company focused on developing innovative therapies for the treatment of cancers, with their flagship product Vicinium representing their first major breakthrough.
